Preventing and Treating Anthracycline Cardiotoxicity: New Insights.
Annu Rev Pharmacol Toxicol
; 61: 309-332, 2021 01 06.
Article
in En
| MEDLINE
| ID: mdl-33022184
ABSTRACT
Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers. Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite more than five decades of research, the biological mechanisms underlying anthracycline cardiotoxicity are not completely understood. In this review, we discuss the incidence, risk factors, types, and pathophysiology of anthracycline cardiotoxicity, as well as methods to prevent and treat this condition. We also summarize and discuss advances made in the last decade in the comprehension of the molecular mechanisms underlying the pathology.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Anthracyclines
/
Neoplasms
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Annu Rev Pharmacol Toxicol
Year:
2021
Document type:
Article